Slide 1 PolyOne Corporation Page 1 PolyOne Investor Presentation KeyBanc 2014 Basic Materials & Packaging Conference Boston, MA September 10, 2014 PolyOne Corporation Page 2 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. S&P 500 -150% -50% 50% 150% 250% 350% 450% 550% POL S&P 500 All time high of $43.34 July 1st, 2014 PolyOne Corporation Page 9 2006 2014 YTD 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 15.2% 12 – 16% Global Specialty Engineered Materials 1.1% 11.8% 12 – 16% Designed Structures & Solutions -- 7.1% 8 – 10% Performance Products & Solutions 5.5% 8.0% 9 – 12% Distribution 2.6% 6.0% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 66% 65 – 75% 3) ROIC* 5.0% 9.9% 15% 4) Adjusted EPS Growth N/A 40% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period (Est. in 2012) PolyOne Corporation Page 10 Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental Share Buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid Single Digit Revenue CAGR PolyOne Corporation Page 11 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Specialty Vitality Index Target ≥ 35% PolyOne Corporation Page 12 Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 4 11 5 10 6 9 3 4 2 15 9 1 10 4 Breakthrough Platform Derivative A Rich Pipeline of Opportunity* Number of Projects 25 14 19 17 18 93 Addressable Market ($ millions) TBD TBD $800 $450 $450 $1,700 *Pipeline as of May 29, 2014 as presented during our Innovation Day PolyOne Corporation Page 13 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 14 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of June 30, 2014 Debt Maturities & Pension Funding – 6/30/14 Net Debt / EBITDA* = 1.8x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of June 30, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 6/30/2014 PolyOne Corporation Page 15 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend Expanding our sales, marketing, and technical capabilities Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin Synergy opportunities Adjacent material solutions Repurchased 1.8 million shares in Q2 2014 Repurchased 8.2 million shares since early 2013  11.8 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture) Manufacturing alignment PolyOne Corporation Page 16 PolyOne Core Values Innovation Collaboration Excellence PolyOne Corporation Page 17 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne?

0962-01 (1).pdf

MEVOPUR LQ for Silicone Elastomers_CN5.17-1 MEVOPUR™ LQ 应用于硅橡胶的液体着色剂和添加剂母粒 应用公告 硅橡胶由于其独特的物理特性组合，例如强度、 耐受度及灵活性等，同时作为一种通过最多生物 相容性及低致敏性测试的聚合物之一，成为了多 种医疗应用的首选材料。 可根据要求提供多种定制化 颜色解决方案 根据ISO 13485/GMP质量体系生产，并拥有变 更控制管理 原材料红外光谱分析和常规批次检测 根据ISO 10993第18部分对正己烷、异丙醇及 水中的可萃取性进行评估 法规支持 原材料根据ISO 10993-1和USP第、 章（VI类）对原材料进行生物评估的预测试 向FDA提交所有标准颜色的DMF/MAF文件 应用 医疗器械，如导管和连接器、注射器针头及无 针连接器 与皮肤接触设备，如可穿戴设备或医疗器械的 柔软触感表面 MEVOPUR LQ 配方可用于要求严苛的应用，包 括： MEVOPUR™-LQ 不透明红（PMS198C） 产品编号：FZ3M415008 MEVOPUR™-LQ 透明红 产品编号：FZ3M415009 MEVOPUR™-LQ 不透明蓝（PMS292C） 产品编号：FZ5M415008 MEVOPUR™-LQ 透明蓝 产品编号：FZ5M415009 MEVOPUR™-LQ 不透明黄（PMS1205C） 产品编号：FZ1M415005 MEVOPUR™-LQ 透明黄 产品编号：FZ1M415006 MEVOPUR™-LQ 不透明绿（PMS346C） 产品编号：FZ6M415008 MEVOPUR™-LQ 透明绿 产品编号：FZ6M415009 MEVOPUR™-LQ 不透明紫（PMS2655C） 产品编号：FZ4M415003 MEVOPUR™-LQ 透明紫 产品编号：FZ4M415004 定制化选择 也可以根据您的需求 定制颜色， 请联系我们。 在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。